EryDel S.p.A. is a Drug Delivery Company specialized in the development of drugs and diagnostics delivered through human red blood cells via a proprietary medical device technology.

Based in Milan (Italy), EryDel develops an innovative red-blood-cell-based drug delivery device for the treatment of rare neurodegenerative diseases. Its proprietary technology relies upon the encapsulation of drugs into red cells taken from the patient’s own blood which are then re-infused into the patient. The company is led by Luca Benatti, CEO, a serial entrepreneur who previously co-founded Newron Pharmaceuticals (NWRN). EryDel’s lead product, EryDex, has received Orphan Drug designation both from the FDA and the EMA for the treatment of Ataxia Telangiectasia (AT), a rare autosomal recessive disorder for which there is currently no established therapy. Most AT patients die in the second decade of life. Next to AT, EryDel’s technology is being developed in a wide range of additional applications.

Biopharmaceuticals

Graziano Seghezzi

Graziano Seghezzi is Managing Partner at Sofinnova Partners which he joined in 2006. He seed funded and was on the Board of GlycoVaxyn which was sold to GlaxoSmithKline in 2015 and Omthera Pharmaceuticals which went public on Nasdaq in 2013, then was sold to AstraZeneca later that year. Graziano als...